Promoted Content Promoted Content

X

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...

All Data

Filters Filter
×
FILTER:
filter News Type
    filter Company
      filter Product Type
        filter Deal Size
          filter Upfront Payment

            Active Filter(s):

            Product Type

            Companies

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Lead Product(s): CAR-T Therapy

            Therapeutic Area: Oncology Product Name: Undisclosed

            Highest Development Status: Discovery Platform Product Type: Cell and Gene therapy

            Partner/Sponsor/Collaborator: Casdin Capital

            Deal Size: $90.0 million Upfront Cash: Undisclosed

            Deal Type: Series A Financing June 16, 2021

            Details:

            The Series A financing will allow the company to accelerate development of the EnfiniT targeting and next generation chimeric antigen receptors (CAR) T cell therapy platform combining the pioneering research from Institut Curie and Memorial Sloan Kettering Cancer Center.